US8759024B2 - Process for the production of riboflavin - Google Patents
Process for the production of riboflavin Download PDFInfo
- Publication number
- US8759024B2 US8759024B2 US13/139,896 US200913139896A US8759024B2 US 8759024 B2 US8759024 B2 US 8759024B2 US 200913139896 A US200913139896 A US 200913139896A US 8759024 B2 US8759024 B2 US 8759024B2
- Authority
- US
- United States
- Prior art keywords
- ccpc
- riboflavin
- microorganism
- nucleic acid
- gene
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active, expires
Links
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 title claims abstract description 190
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 title claims abstract description 96
- 229960002477 riboflavin Drugs 0.000 title claims abstract description 96
- 239000002151 riboflavin Substances 0.000 title claims abstract description 94
- 235000019192 riboflavin Nutrition 0.000 title claims abstract description 94
- 238000000034 method Methods 0.000 title claims abstract description 51
- 230000008569 process Effects 0.000 title claims abstract description 41
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 16
- 230000000694 effects Effects 0.000 claims abstract description 43
- 230000014509 gene expression Effects 0.000 claims abstract description 27
- 108090000623 proteins and genes Proteins 0.000 claims description 97
- 235000014469 Bacillus subtilis Nutrition 0.000 claims description 34
- 108091023040 Transcription factor Proteins 0.000 claims description 34
- 102000040945 Transcription factor Human genes 0.000 claims description 34
- 150000007523 nucleic acids Chemical class 0.000 claims description 33
- 230000027455 binding Effects 0.000 claims description 31
- 102000039446 nucleic acids Human genes 0.000 claims description 31
- 108020004707 nucleic acids Proteins 0.000 claims description 31
- 244000005700 microbiome Species 0.000 claims description 27
- 244000063299 Bacillus subtilis Species 0.000 claims description 25
- 230000035772 mutation Effects 0.000 claims description 22
- 102000004169 proteins and genes Human genes 0.000 claims description 15
- 239000012634 fragment Substances 0.000 claims description 13
- 241000193744 Bacillus amyloliquefaciens Species 0.000 claims description 8
- 239000002253 acid Substances 0.000 claims description 8
- 239000002773 nucleotide Substances 0.000 claims description 8
- 125000003729 nucleotide group Chemical group 0.000 claims description 8
- 241000193830 Bacillus <bacterium> Species 0.000 claims description 7
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 7
- 238000012258 culturing Methods 0.000 claims description 7
- 238000000855 fermentation Methods 0.000 claims description 6
- 230000004151 fermentation Effects 0.000 claims description 6
- 239000001963 growth medium Substances 0.000 claims description 5
- 238000009396 hybridization Methods 0.000 claims description 5
- 238000002955 isolation Methods 0.000 claims description 2
- 230000002103 transcriptional effect Effects 0.000 claims 1
- 230000000813 microbial effect Effects 0.000 abstract description 6
- 108090000790 Enzymes Proteins 0.000 abstract description 5
- 102000004190 Enzymes Human genes 0.000 abstract description 5
- 238000012262 fermentative production Methods 0.000 abstract description 4
- 230000033228 biological regulation Effects 0.000 abstract description 3
- 229930003471 Vitamin B2 Natural products 0.000 abstract description 2
- 235000019164 vitamin B2 Nutrition 0.000 abstract description 2
- 239000011716 vitamin B2 Substances 0.000 abstract description 2
- 210000004027 cell Anatomy 0.000 description 80
- 230000015572 biosynthetic process Effects 0.000 description 22
- 230000001105 regulatory effect Effects 0.000 description 19
- 238000003786 synthesis reaction Methods 0.000 description 19
- 239000000047 product Substances 0.000 description 17
- 230000004048 modification Effects 0.000 description 14
- 238000012986 modification Methods 0.000 description 14
- 108020004414 DNA Proteins 0.000 description 13
- 239000002609 medium Substances 0.000 description 13
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 12
- 229930193140 Neomycin Natural products 0.000 description 11
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 11
- 229960004927 neomycin Drugs 0.000 description 11
- 239000000243 solution Substances 0.000 description 11
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- 101100268898 Streptococcus mutans serotype c (strain ATCC 700610 / UA159) acn gene Proteins 0.000 description 8
- 101150113917 acnA gene Proteins 0.000 description 8
- 101150074491 citB gene Proteins 0.000 description 8
- 101150028648 citZ gene Proteins 0.000 description 8
- 101150118937 dpiA gene Proteins 0.000 description 8
- FVTCRASFADXXNN-SCRDCRAPSA-N flavin mononucleotide Chemical compound OP(=O)(O)OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O FVTCRASFADXXNN-SCRDCRAPSA-N 0.000 description 8
- 239000000523 sample Substances 0.000 description 8
- 241000276408 Bacillus subtilis subsp. subtilis str. 168 Species 0.000 description 7
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 7
- 230000000692 anti-sense effect Effects 0.000 description 7
- 229910052799 carbon Inorganic materials 0.000 description 7
- 238000006243 chemical reaction Methods 0.000 description 7
- 230000003247 decreasing effect Effects 0.000 description 7
- 239000008103 glucose Substances 0.000 description 7
- 150000003839 salts Chemical class 0.000 description 7
- 238000013518 transcription Methods 0.000 description 7
- 230000035897 transcription Effects 0.000 description 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- VWWQXMAJTJZDQX-UYBVJOGSSA-N flavin adenine dinucleotide Chemical compound C1=NC2=C(N)N=CN=C2N1[C@@H]([C@H](O)[C@@H]1O)O[C@@H]1CO[P@](O)(=O)O[P@@](O)(=O)OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C2=NC(=O)NC(=O)C2=NC2=C1C=C(C)C(C)=C2 VWWQXMAJTJZDQX-UYBVJOGSSA-N 0.000 description 6
- 235000019162 flavin adenine dinucleotide Nutrition 0.000 description 6
- 239000011714 flavin adenine dinucleotide Substances 0.000 description 6
- 239000011768 flavin mononucleotide Substances 0.000 description 6
- 229940013640 flavin mononucleotide Drugs 0.000 description 6
- FVTCRASFADXXNN-UHFFFAOYSA-N flavin mononucleotide Natural products OP(=O)(O)OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O FVTCRASFADXXNN-UHFFFAOYSA-N 0.000 description 6
- 229940093632 flavin-adenine dinucleotide Drugs 0.000 description 6
- 238000004128 high performance liquid chromatography Methods 0.000 description 6
- 235000019231 riboflavin-5'-phosphate Nutrition 0.000 description 6
- 239000000758 substrate Substances 0.000 description 6
- 238000012239 gene modification Methods 0.000 description 5
- 230000005017 genetic modification Effects 0.000 description 5
- 235000013617 genetically modified food Nutrition 0.000 description 5
- 230000009467 reduction Effects 0.000 description 5
- 239000011573 trace mineral Substances 0.000 description 5
- 238000010361 transduction Methods 0.000 description 5
- 230000026683 transduction Effects 0.000 description 5
- 238000005406 washing Methods 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 229910001868 water Inorganic materials 0.000 description 5
- 108091081024 Start codon Proteins 0.000 description 4
- 239000006166 lysate Substances 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 239000013612 plasmid Substances 0.000 description 4
- 239000002243 precursor Substances 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 150000003287 riboflavins Chemical class 0.000 description 4
- 101150042065 spo0A gene Proteins 0.000 description 4
- 235000013619 trace mineral Nutrition 0.000 description 4
- 238000012546 transfer Methods 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 3
- 229910019142 PO4 Inorganic materials 0.000 description 3
- MUPFEKGTMRGPLJ-RMMQSMQOSA-N Raffinose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 MUPFEKGTMRGPLJ-RMMQSMQOSA-N 0.000 description 3
- MUPFEKGTMRGPLJ-UHFFFAOYSA-N UNPD196149 Natural products OC1C(O)C(CO)OC1(CO)OC1C(O)C(O)C(O)C(COC2C(C(O)C(O)C(CO)O2)O)O1 MUPFEKGTMRGPLJ-UHFFFAOYSA-N 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 230000004907 flux Effects 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 235000011187 glycerol Nutrition 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 238000003780 insertion Methods 0.000 description 3
- 230000037431 insertion Effects 0.000 description 3
- 230000002503 metabolic effect Effects 0.000 description 3
- 239000010452 phosphate Substances 0.000 description 3
- 229920001184 polypeptide Polymers 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- MUPFEKGTMRGPLJ-ZQSKZDJDSA-N raffinose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)O1 MUPFEKGTMRGPLJ-ZQSKZDJDSA-N 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 230000001629 suppression Effects 0.000 description 3
- JRMUNVKIHCOMHV-UHFFFAOYSA-M tetrabutylammonium bromide Chemical compound [Br-].CCCC[N+](CCCC)(CCCC)CCCC JRMUNVKIHCOMHV-UHFFFAOYSA-M 0.000 description 3
- 238000013519 translation Methods 0.000 description 3
- 230000004102 tricarboxylic acid cycle Effects 0.000 description 3
- 230000009452 underexpressoin Effects 0.000 description 3
- SXDXRJZUAJBNFL-UHFFFAOYSA-N 1-Deoxy-1-(6,7-dimethyl-2,4-dioxo-2,3,4,8-tetrahydropteridin-8-yl)-D-ribitol Natural products OCC(O)C(O)C(O)CN1C(C)=C(C)N=C2C1=NC(=O)NC2=O SXDXRJZUAJBNFL-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 239000002028 Biomass Substances 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 2
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 2
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
- XKMLYUALXHKNFT-UUOKFMHZSA-N Guanosine-5'-triphosphate Chemical compound C1=2NC(N)=NC(=O)C=2N=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O XKMLYUALXHKNFT-UUOKFMHZSA-N 0.000 description 2
- 229910004616 Na2MoO4.2H2 O Inorganic materials 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical group O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- 230000010632 Transcription Factor Activity Effects 0.000 description 2
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000012736 aqueous medium Substances 0.000 description 2
- 244000052616 bacterial pathogen Species 0.000 description 2
- 238000011138 biotechnological process Methods 0.000 description 2
- 239000001110 calcium chloride Substances 0.000 description 2
- 229910001628 calcium chloride Inorganic materials 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 229940041514 candida albicans extract Drugs 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- MPTQRFCYZCXJFQ-UHFFFAOYSA-L copper(II) chloride dihydrate Chemical compound O.O.[Cl-].[Cl-].[Cu+2] MPTQRFCYZCXJFQ-UHFFFAOYSA-L 0.000 description 2
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 230000002074 deregulated effect Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 239000008121 dextrose Substances 0.000 description 2
- 235000013681 dietary sucrose Nutrition 0.000 description 2
- 210000003527 eukaryotic cell Anatomy 0.000 description 2
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000002779 inactivation Effects 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 238000010369 molecular cloning Methods 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 230000001323 posttranslational effect Effects 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 239000013587 production medium Substances 0.000 description 2
- 210000001236 prokaryotic cell Anatomy 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 238000004088 simulation Methods 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- FDEIWTXVNPKYDL-UHFFFAOYSA-N sodium molybdate dihydrate Chemical compound O.O.[Na+].[Na+].[O-][Mo]([O-])(=O)=O FDEIWTXVNPKYDL-UHFFFAOYSA-N 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 229960004793 sucrose Drugs 0.000 description 2
- 230000009897 systematic effect Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 239000012138 yeast extract Substances 0.000 description 2
- 239000011592 zinc chloride Substances 0.000 description 2
- JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- 108020003589 5' Untranslated Regions Proteins 0.000 description 1
- XKQZIXVJVUPORE-RPDRRWSUSA-N 5-amino-6-(D-ribitylamino)uracil Chemical compound NC1=C(NC[C@H](O)[C@H](O)[C@H](O)CO)NC(=O)NC1=O XKQZIXVJVUPORE-RPDRRWSUSA-N 0.000 description 1
- SXDXRJZUAJBNFL-XKSSXDPKSA-N 6,7-dimethyl-8-(1-D-ribityl)lumazine Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C(C)=C(C)N=C2C1=NC(=O)NC2=O SXDXRJZUAJBNFL-XKSSXDPKSA-N 0.000 description 1
- 108700028369 Alleles Proteins 0.000 description 1
- 241000972773 Aulopiformes Species 0.000 description 1
- 241000193738 Bacillus anthracis Species 0.000 description 1
- 241000193755 Bacillus cereus Species 0.000 description 1
- 241000006382 Bacillus halodurans Species 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 241000186216 Corynebacterium Species 0.000 description 1
- 125000002353 D-glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
- FNZLKVNUWIIPSJ-UHNVWZDZSA-N D-ribulose 5-phosphate Chemical compound OCC(=O)[C@H](O)[C@H](O)COP(O)(O)=O FNZLKVNUWIIPSJ-UHNVWZDZSA-N 0.000 description 1
- 230000004568 DNA-binding Effects 0.000 description 1
- 241000235036 Debaryomyces hansenii Species 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241001465321 Eremothecium Species 0.000 description 1
- 241001465328 Eremothecium gossypii Species 0.000 description 1
- 241000206602 Eukaryota Species 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- 108010057573 Flavoproteins Proteins 0.000 description 1
- 102000003983 Flavoproteins Human genes 0.000 description 1
- 241000193385 Geobacillus stearothermophilus Species 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 239000007836 KH2PO4 Substances 0.000 description 1
- 101100356737 Listeria monocytogenes serovar 1/2a (strain ATCC BAA-679 / EGD-e) ribCF gene Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- BACYUWVYYTXETD-UHFFFAOYSA-N N-Lauroylsarcosine Chemical compound CCCCCCCCCCCC(=O)N(C)CC(O)=O BACYUWVYYTXETD-UHFFFAOYSA-N 0.000 description 1
- 238000000636 Northern blotting Methods 0.000 description 1
- 241000364057 Peoria Species 0.000 description 1
- 239000001888 Peptone Substances 0.000 description 1
- 108010080698 Peptones Proteins 0.000 description 1
- 108010002747 Pfu DNA polymerase Proteins 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- FNZLKVNUWIIPSJ-UHFFFAOYSA-N Rbl5P Natural products OCC(=O)C(O)C(O)COP(O)(O)=O FNZLKVNUWIIPSJ-UHFFFAOYSA-N 0.000 description 1
- 241000831652 Salinivibrio sharmensis Species 0.000 description 1
- 101100010154 Streptomyces ribosidificus rbmA gene Proteins 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000009603 aerobic growth Effects 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940065181 bacillus anthracis Drugs 0.000 description 1
- LFYJSSARVMHQJB-QIXNEVBVSA-N bakuchiol Chemical compound CC(C)=CCC[C@@](C)(C=C)\C=C\C1=CC=C(O)C=C1 LFYJSSARVMHQJB-QIXNEVBVSA-N 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 238000004422 calculation algorithm Methods 0.000 description 1
- 210000000692 cap cell Anatomy 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000004590 computer program Methods 0.000 description 1
- 238000010924 continuous production Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 229940104302 cytosine Drugs 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 230000003831 deregulation Effects 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- PXEDJBXQKAGXNJ-QTNFYWBSSA-L disodium L-glutamate Chemical compound [Na+].[Na+].[O-]C(=O)[C@@H](N)CCC([O-])=O PXEDJBXQKAGXNJ-QTNFYWBSSA-L 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000008570 general process Effects 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000006801 homologous recombination Effects 0.000 description 1
- 238000002744 homologous recombination Methods 0.000 description 1
- XKQZIXVJVUPORE-UHFFFAOYSA-N hyoscyamilactol Natural products NC1=C(NCC(O)C(O)C(O)CO)NC(=O)NC1=O XKQZIXVJVUPORE-UHFFFAOYSA-N 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- DHRRIBDTHFBPNG-UHFFFAOYSA-L magnesium dichloride hexahydrate Chemical compound O.O.O.O.O.O.[Mg+2].[Cl-].[Cl-] DHRRIBDTHFBPNG-UHFFFAOYSA-L 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 229940099596 manganese sulfate Drugs 0.000 description 1
- 239000011702 manganese sulphate Substances 0.000 description 1
- 235000007079 manganese sulphate Nutrition 0.000 description 1
- SQQMAOCOWKFBNP-UHFFFAOYSA-L manganese(II) sulfate Chemical compound [Mn+2].[O-]S([O-])(=O)=O SQQMAOCOWKFBNP-UHFFFAOYSA-L 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000037353 metabolic pathway Effects 0.000 description 1
- 230000002906 microbiologic effect Effects 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 108091005573 modified proteins Proteins 0.000 description 1
- 102000035118 modified proteins Human genes 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 235000013923 monosodium glutamate Nutrition 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 230000004108 pentose phosphate pathway Effects 0.000 description 1
- 235000019319 peptone Nutrition 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 1
- 239000008057 potassium phosphate buffer Substances 0.000 description 1
- OTYBMLCTZGSZBG-UHFFFAOYSA-L potassium sulfate Chemical compound [K+].[K+].[O-]S([O-])(=O)=O OTYBMLCTZGSZBG-UHFFFAOYSA-L 0.000 description 1
- 229910052939 potassium sulfate Inorganic materials 0.000 description 1
- 230000004952 protein activity Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000012264 purified product Substances 0.000 description 1
- 230000004144 purine metabolism Effects 0.000 description 1
- 238000006479 redox reaction Methods 0.000 description 1
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 101150060382 ribC gene Proteins 0.000 description 1
- 101150003625 ribD gene Proteins 0.000 description 1
- 101150073450 ribE gene Proteins 0.000 description 1
- 235000019515 salmon Nutrition 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 229940073490 sodium glutamate Drugs 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
- 101150015398 veg gene Proteins 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P25/00—Preparation of compounds containing alloxazine or isoalloxazine nucleus, e.g. riboflavin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/32—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Bacillus (G)
Definitions
- the invention relates to processes and means for the biotechnologically fermentative production of riboflavin (hereinafter also referred to as vitamin B2) and means for the implementation of this process, in particular a modified microbial host cell with increased riboflavin yield.
- the invention thus provides new processes and means for the regulation of the expression of enzyme activities involved in the riboflavin production of the host cell.
- Riboflavin is a precursor molecule of flavin mononucleotide (FMN) and flavin adenine dinucleotide (FAD). These are essential cofactors for a large number of enzymatic redox reactions in biological cells and organisms. Riboflavin is thus an important additive in the food and animal feed industry. In microorganisms and plants, riboflavin is as a rule synthesized via seven enzymatic reactions from guanosine triphosphate (GTP) from the purine metabolism and ribulose-5-phosphate from the pentose phosphate pathway.
- GTP guanosine triphosphate
- riboflavin are produced biotechnologically in various microorganisms.
- the most important host organisms are bacilli, in particular Bacillus subtilis .
- Bacillus subtilis Apart from these, other microbial cells, including lower eukaryotes, are also used. Examples are the organisms Eremothecium ashbyii, Ashbya gossypii and Candida famata.
- CcpC has a positive influence on the riboflavin production rate.
- CcpC belongs to the family of the LysR transcription factors and is known to regulate genes which code for enzyme activities of the tricarboxylic acid cycle (TCA), above all citB and citZ.
- TCA tricarboxylic acid cycle
- CcpC tricarboxylic acid cycle
- the riboflavin yield is directly dependent on the activity and/or intracellular concentration of the transcription factor CcpC.
- Reduced activity of CcpC leads to an increase in the yield. This effect was surprising and not foreseeable from the state of the art, since the enzyme activities in the TCA known to be regulated by CcpC have no direct connection with the metabolic pathways of riboflavin synthesis.
- biomass production that is in particular the growth rate of the cells modified according to the invention, in particular CcpC-depleted cells, for example ccpC knockout transformants of Bacillus subtilis , remains essentially unchanged.
- the present invention thus relates to a modified riboflavin-producing cell or cell line, prokaryotic or eukaryotic cell, in particular a microbial cell, which is characterized in that the activity or concentration of the transcription factor of the CcpC type and/or a homolog or ortholog thereof present and/or expressed in the cell is modified, in particular reduced. Through this modification the cell or cell line is enabled for increased riboflavin production.
- a modified riboflavin-producing microorganism wherein the expression and/or the activity of the transcription factor of the CcpC type is reduced, preferably by at least 25%, in comparison to a non-modified or wild type microorganism.
- the aforesaid cell or cell line is modified such that the gene coding for CcpC is either not expressed at all (suppression of expression) or at least exhibits reduced expression (underexpression), which leads to absent or decreased/reduced activity of the CcpC protein in said cell/cell line.
- the cell/cell line is preferably a CcpC-depleted mutant or transformant, in particular a knockout mutant of at least one gene coding for CcpC and/or a homolog and/or ortholog thereof.
- Reduced is understood to mean both decreased and in particular absent activity of the CcpC protein, or a homolog or ortholog thereof, in its function as a transcription factor, and also decreased and in particular absent expression of the ccpC gene or a homolog or ortholog thereof, which as a result leads to a low copy number or concentration of the gene product CcpC in the cell, in particular a CcpC-depleted cell.
- Reduced expression is understood to mean a decrease by at least 25%, preferably at least 50, 75, 80, 90, 95, 98 or 100% based on the expression of the ccpC gene in a non-modified (CcpC wild type) cell/cell line. This reduction relates both to the activity of the gene and also the corresponding gene product.
- ccpC gene and/or its gene product is suppressed, “knocked-out” or its function (activity) impaired, in particular in comparison to the CcpC wild type, as it is expressed for example in bacilli, preferably in the organism Bacillus subtilis.
- Suitable processes are for example a Northern blot or the use of “gene chip” processes for the measurement of the activity of the ccpC gene and a Western blot by means of specific antibodies against CcpC or a quantitative “2-D SDS-PAGE gel” for the determination of the protein concentration in the cell.
- the activity of a transcription factor, in particular CcpC can also be determined indirectly via “gel shift” experiments wherein the quantity of bound CcpC at the corresponding binding sites of the gene to be regulated, such as for example citB or citZ, is measured.
- Suitable cells or cell lines for the implementation of the present invention are all known riboflavin-producing cells in which the expression of the ccpC gene or homolog or ortholog thereof can be reduced.
- Examples are prokaryotic or eukaryotic cells, preferably Gram negative or Gram positive bacteria, in particular a microbial cell such as for example Bacillus, Corynebacterium or Pseudomonas .
- Preferred are cells of the genus Bacillus , e.g.
- Bacillus anthracis Bacillus cereus, Bacillus stearothermophilus, Bacillus halodurans, Bacillus amyloliquifaciens or Bacillus subtilis, Bacillus subtilis being particularly preferred, such as for example B. subtilis 168.
- a particularly preferred host cell which is suitable for the present invention is B. subtilis RB50::[pRF69] n , which comprises multiple copies (e.g. ca. 5 to ca. 20 copies) of the plasmid pRF69, which codes for a modified riboflavin (rib) operon, wherein the modification consists in the insertion of a strong promoter P spo15 , which results in the intensification of the transcription of the riboflavin genes (see for example EP 405370 and Perkins et al., J. Ind. Microbiol. Biotechnol., 22:8-18, 1999 for the construction of the strain and the culturing conditions for increasing the riboflavin synthesis).
- rib riboflavin
- subtilis RB 50 and the plasmid pRF69 are respectively deposited in accordance with the provisions of the Budapest Treaty at the “Agricultural Research Culture Collection” (NRRL), Peoria, Ill., USA, Culture Collection Division under the number (“accession number”) B 18502 and at the “American Type Culture Collection” (ATCC), P.O. Box 1549, Manassas, Va. 20108 USA under the number (“accession number”) ATCC 68338.
- the modification in the ccpC gene is effected in a strain of the genus Bacillus , in particular Bacillus subtilis .
- Bacillus subtilis particularly preferred here is a Bacillus strain as host cell, in particular B. subtilis strain, deregulated in the riboflavin operon. Examples of a deregulated riboflavin operon are known and include so-called “ribO” and “ribC” mutations.
- the deregulation causes intensified gene expression of the rib genes.
- a host cell in particular Bacillus subtilis , wherein the gene which codes for the transcription regulator Spo0A is (over)expressed.
- the present invention is implemented in B. subtilis RB50 which is mutated to the effect that an active form of the spo0A gene is expressed.
- microorganisms suitable for the present invention are publicly available via for example the following deposition sites: German Collection of Microorganisms and Cell Cultures (DSMZ), Inhoffenstrasse 7B, D-38124 Brunswick, Germany, “NITE Biological Resource Center”, 2-5-8, Kazusakamatari, Kisarazu-shi, Chiba, 292-0818, Japan (previously known as “Institute for Fermentation”, Osaka (IFO), 17-85, Juso-honmachi 2-chome, Yodogawa-ku, Osaka 532-8686, Japan) or the “ Bacillus Genetic Stock Center” (BGSC), The Ohio State University, Columbus, Ohio 43210 USA.
- the aforesaid microorganisms also include synonyms and basonyms with the same physiological properties, which are laid down by the “International Code of Nomenclature of Prokaryotes”.
- the nomenclature of the microorganisms in the present invention is that which was officially accepted by the “International Committee on Systematics of Prokaryotes and the Bacteriology and Applied Microbiology Division of the International Union of Microbiological Societies” and was officially published in the “International Journal of Systematic and Evolutionary Microbiology” (IJSEM) at the time of the priority application.
- the invention relates to mutated and in particular non-functional genes.
- the invention relates to mutated and in particular non-functional transcripts therefrom.
- the invention also relates to mutated and in particular non-functional polypeptides therefrom.
- Such mutated structures are in the sense of the invention particularly suitable in order to provide genetically modified host cells wherein the function of the CcpC wild type or a homolog or ortholog thereof is reduced or inhibited.
- an essential element of the teaching according to the invention is to reduce the effective, that is active, concentration of the ccpC gene, the CcpC transcript or the translated transcription factor in the cell in order to increase the riboflavin biosynthesis in a host cell.
- concentration of the ccpC gene, the CcpC transcript or the translated transcription factor in the cell in order to increase the riboflavin biosynthesis in a host cell.
- the reduction of the activity and/or the intracellular concentration of CcpC or homologs or orthologs thereof can be achieved in a manner known per se.
- Those skilled in the art know biotechnological processes and means appropriate for obtaining so-called CcpC-depleted or ccpC knockout mutants or transformants. The invention is therefore not limited to the preferred variants and embodiments described in more detail herein.
- mutation is understood to mean any genetic modification, that is in particular modification at the molecular level, of a nucleic acid molecule which leads to a non-functional “mutated” gene product.
- it is understood to mean a change in the genome of a microorganism, which interferes with the synthesis of the gene product, that is herein with the synthesis of the transcription factor of the CcpC type and/or leads to the expression of a “mutated” or modified polypeptide, which has a changed “mutated” amino acid sequence and the function whereof has been partly or completely lost in comparison to the CcpC wild type.
- a mutation according to the invention in the gene or in the gene product leads to changes in at least one step in the expression selected from transcription, translation and if applicable post-translational modification.
- This mutation is preferably selected from: point mutation, deletion, substitution, insertion and inversion of at least one nucleotide within the gene sequence.
- the measures for the genetic mutation are however not limited to these preferred embodiments. Those skilled in the art know further possibilities for placing mutations in a gene.
- the purpose of the mutations according to the invention is the suppression of the expression of at least one gene coding for CcpC.
- a purpose connected therewith is the expression of a modified transcription factor which compared to the wild type displays a decreased activity, in particular regulatory activity, in the cell.
- the “mutation” relates not only to the direct modification of the coding sequence of a gene, but also to the modification of other structures or sequences which are connected with expression. These preferably include structures of the operon of the gene, in particular regulating structures, preferably selected from promoters, regulators, operators, transcription factor binding sites, terminators and cofactors thereof, without wishing to be limited exclusively thereto.
- function particularly in connection with the terms “function-relevant”, “function-analogous” and “functioning”, is understood to mean the transcription factor function of the CcpC wild type, or a homolog or ortholog thereof for the regulation of the expression of operons or genes, which has an operator structure to which the transcription factor binds.
- the function of a protein, in particular of a transcription factor such as for example CcpC, is according to the invention also expressed as activity, where the transcription factor function of the CcpC wild type corresponds to a transcription factor activity of 100%.
- a subject matter of the invention is an isolated nucleic acid molecule which represents the ccpC gene, and homologs and orthologs thereof.
- the invention relates in particular to this gene as represented in the nucleotide sequence SEQ ID No.:1 and as it occurs for example in the organism Bacillus subtilis .
- the invention also relates to the gene product thereof (CcpC protein), represented for example by the amino acid sequence SEQ ID No.:2.
- the gene ccpC is in particular part of an operon in one of the aforesaid suitable host cells, preferably in Bacillus subtilis .
- CcpC sequences are known to those skilled in the art, for example performing a “BLAST” search in a suitable database such as for example EMBL, Genbank, SwissProt, etc. These sequences serve as CcpC wild type, which are then modified according to the present invention, which in an appropriate host organism leads to an increase in the riboflavin biosynthesis.
- a microorganism which contains this wild type sequence is referred to in connection with the present invention as a wild type microorganism.
- the invention thus relates to a—preferably isolated—mutated (modified) nucleic acid molecule, which codes for a “mutated” transcription factor, which is in particular derived from the CcpC type or a homolog or ortholog thereof, where the non-mutated (wild type) nucleic acid molecule is selected from the group consisting of:
- nucleic acid molecules which comprise or consist of the nucleotide sequence SEQ ID No.:1;
- nucleic acid molecules which code for a polyamino acid molecule (protein) comprising or consisting of the amino acid sequence SEQ ID No.:2;
- nucleic acid molecules which under stringent conditions hybridize with one of the nucleic acid molecules of a) or b);
- nucleic acid molecules according to a) or b), which code for proteins with the function/activity of a transcription factor of the CcpC type, where the mutated nucleic acid molecule exhibits at least one genetic mutation which leads to reduced activity of the CcpC protein in comparison to the activity of the CcpC wild type.
- the ccpC gene is completely knocked out (so-called knockout mutation).
- a further subject matter of the invention is a polyamino acid molecule (protein or polypeptide), preferably a molecule present as isolated, selected from the group consisting of:
- the protein of a) to d) is the wild type CcpC, which—as described above—is modified, which results in a reduction of the activity as transcription factor.
- the invention also relates to such nucleic acid molecules or proteins which exhibit considerable sequence identity, that is in particular considerable “homology”, towards those in the preferred SEQ ID No.:1 or SEQ ID No.:2 respectively.
- this is understood to mean a homology of at least 70%, preferably at least 75%, particularly preferably at least 80%, at least 85%, at least 90%, at least 95% and at least 98% sequence identity.
- the sequence relates to identity to SEQ ID No.:1 or SEQ ID No.:2 respectively over the whole length.
- the aforesaid sequence identity relates exclusively to the function-relevant regions of the sequences SEQ ID No.:1 and SEQ ID No.:2. Examples of such regions are the DNA binding domains in the ccpC gene. Those skilled in the art know programs for identifying these gene regions.
- hybridization under “stringent conditions” can be understood as one criterion.
- stringent conditions reference is made to the known technical context as described for example in Maniatis et al., 1989: “Molecular cloning, a laboratory manual”, 2 nd Edition, Cold Spring Harbours Laboratory, N.Y. “Stringent conditions” are dependent on the actual sequence. As a rule, this is understood to mean a hybridization temperature which is 5 to 10 K lower than the melting point of a specific sequence, at which 50% sequence-identical complementary probes hybridize to the target sequence. Conditions under which nucleic acid sequences of at least 50%, 60, 70% or particularly preferably of at least 80%, most preferably of at least 85% to 90%, in particular of at least 95% are homologous to one another are preferred.
- the reaction is performed in 6 ⁇ sodium chloride/sodium citrate (SSC) at ca. 45° C. with subsequent washing in 1 ⁇ SSC, 0.1% SDS at 50° C., preferably 55° C., particularly preferably 60° C., especially preferably at 65° C.
- SSC sodium chloride/sodium citrate
- “highly stringent conditions” for example comprise an incubation for 2 hours to 4 days at 42° C.
- DIG-labeled probe prepared for example by means of the “DIG labeling system”, Roche Diagnostics GmbH, 68298 Mannheim, Germany
- a solution such as for example “DigEasyHyb solution” (Roche Diagnostics GmbH) and the optional addition of 100 ⁇ g/ml salmon sperm nucleic acid, or in a solution containing 50% formamide, 5 ⁇ SSC, 0.02% SDS, 0.1% N-laurylsarcosine and 2% “blocking reagent” (Roche Diagnostics GmbH), followed by washing twice for 5 to 15 minutes in 2 ⁇ SSC, 0.1% SDS at room temperature and washing twice for 15 to 30 minutes in 0.5 ⁇ SSC, 0.1% SDS or in 0.1 ⁇ SSC, 0.1% SDS at 65 to 68° C.
- both sequences are adjusted for the optimal comparison (thus for example gaps are introduced into one sequence for the optimal alignment of the two sequences).
- the nucleotides at corresponding positions are then compared. If a position in the first nucleic acid sequence is occupied by the same nucleotide at the corresponding position in the second sequence, both molecules are identical at this position, which corresponds to a homology or identity of 100%.
- the sequences to be compared preferably have the same length.
- GAP Garnier-Prot al.
- orthologs should be understood to mean genes of different genera which have all arisen starting from one common original gene. Normally, the function of these orthologous genes is conserved during evolution. The identification of orthologs is important in order to be able to make a reliable prediction of gene function in previously unsequenced genomes.
- the invention provides the modification, in particular reducing the activity, of the binding affinity of the transcription factor CcpC, or a homolog or ortholog thereof, and/or the interaction thereof with an operon of the regulated gene, in particular the transcription factor binding structure, and/or of a cofactor thereof, such that modified or “mutated” gene products derived from CcpC, or homologs or orthologs thereof, i.e. proteins, are obtained showing decreased or no binding activity and/or interaction with the operator structures which are connected with the regulated gene or operon.
- this is carried out by direct genetic modification of the original ccpC gene (wild type) or homologs or orthologs thereof, so that a gene product with a modified “mutated” amino acid sequence is obtained, in particular with a modified protein structure.
- this is carried out by modifying at least one process, selected from transcription, translation and if applicable post-translational processing, particularly preferred modification of at least one molecular structure connected with these processes or of a cofactor for these.
- This is in particular effected by use of at least one structure or of a construct, which binds and/or inactivates the structure or sequence involved in at least one of these processes.
- This structure or the construct is preferably selected from antisense constructs and antibodies, without being exclusively limited thereto.
- the activity and/or concentration of the transcription factor CcpC, or homologs or orthologs thereof is directly reduced by means of specific inhibitors.
- specific inhibitors are antisense constructs of the CcpC gene, or homologs or orthologs thereof, or of other structurally related nucleic acid molecules according to the invention, which are transiently or stably introduced into the host cell in a manner known per se and which are expressed therein.
- the invention provides the modification, in particular reduction of concentration/activity, i.e. in particular the copy number, of expression of the transcription factor CcpC and its homologs or orthologs, respectively, and/or if necessary the expression of a Co-factor thereof, in particular to reduce or completely suppress said expression.
- this is effected by direct genetic modification of the operon of the ccpC gene or homologs or orthologs thereof.
- the modification of the promoter controlling the expression of the gene is provided for this, and preferably such that underexpression occurs or the expression does not occur at all, in other words is “knocked out”.
- this is effected by modulating at least one process, selected from transcription, translation and if applicable post-translational processing, preferably in particular of at least one molecular structure connected with these processes or of a cofactor for these.
- modulating at least one process selected from transcription, translation and if applicable post-translational processing, preferably in particular of at least one molecular structure connected with these processes or of a cofactor for these.
- These include in particular knockout mutations, which can for example be obtained by means of homologous recombination, and also the use of antisense constructs in a manner known per se.
- nucleic acids or antisense constructs according to the invention can be introduced into the host cell by generally known methods.
- Preferred methods are the disintegration of the cell wall and/or membrane of the host cell preferably by electroporation, detergents or analogous means and alternatively or preferably in addition by ballistic processes (e.g. “gene gun”) or analogous processes, without the invention being limited to these processes and means.
- one aspect of the invention is an externally and in particular synthetically produced DNA or RNA molecule with a nucleotide sequence according to the invention in antisense orientation, which can be introduced into the host cell.
- This in particular includes vectors which comprise one or more copies of this nucleic acid molecule in antisense orientation.
- a preferred embodiment of the invention is a modified microbial cell which is modified for suppression of the expression of CcpC, or homologs or orthologs thereof.
- the cell is modified for underexpression of CcpC, or homologs or orthologs thereof.
- the cell is a knockout mutant of at least one gene which codes for CcpC.
- the invention thus also includes modified cells which are knockout mutants of homologs of the CcpC coding gene of Bacillus subtilis .
- the invention thus also includes knockout mutants of orthologs of the CcpC coding gene of Bacillus subtilis .
- the invention also includes knockout mutants of other function-analogs of CcpC and the gene(s) thereof.
- the genetic modification takes place at least one and preferably several binding structures and fragments thereof of the CcpC transcription factor.
- These are preferably the operator structures of the genes regulated by CcpC in the host cell. Regulated genes are in particular citB and citZ, without the invention being intended to be limited thereto.
- the binding of the transcription factor to the operator should be prevented or decreased, so that the regulating effect with regard to the transcription of the gene occurs to a reduced extent or not at all.
- Binding sequences of the regulated genes citB and citZ and in the ccpC gene itself are for example published/referenced in the “database of transcriptional regulation in Bacillus subtilis ” (DBTBS; see http://dbtbs.hgc.jp/).
- Examples of known binding sequences in regulatory sequences of the ccpC gene itself are located at position ⁇ 10 to +15 (SEQ ID No.:3), in particular position ⁇ 5 to +10 (SEQ ID No.:8), relative to the start codon.
- Known binding sequences of citB are located at position ⁇ 75 to ⁇ 52 (SEQ ID No.:4), in particular position ⁇ 73 to ⁇ 68 (SEQ ID No.:9) or position ⁇ 64 to ⁇ 60 (SEQ ID No.:10), and at position ⁇ 35 to ⁇ 22 (SEQ ID No.:5) or position ⁇ 35 to ⁇ 17 (SEQ ID No.:11), in particular position ⁇ 27 to ⁇ 22 (SEQ ID No.:12), relative to the start codon, and known binding sequences of citZ are located at position ⁇ 11 to +5 (SEQ ID No.:6), in particular position ⁇ 11 to ⁇ 8 (SEQ ID No.:13), and at position +21 to +44 (SEQ ID No.:7), in particular position +23 to +26 (SEQ ID No.:14) or position +34 to +37 (SEQ ID No.:15), relative to the start codon.
- the aforesaid known binding sequences and the corresponding operons are listed in table 1.
- the present invention thus relates to a modified host cell which contains a modification/mutation in the ccpC gene which leads to reduced expression of the gene (see above).
- the host cell can also be modified such that it comprises a modification/mutation in a binding sequence for the ccpC gene product, preferably in one of the binding sequences described above according to SEQ ID No.:3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 or 15, whereby the binding of CcpC is reduced.
- This reduced binding should be understood as reduced activity of CcpC, as described above, a reduced activity of at least 25% in comparison to the activity of the wild type being preferred, which corresponds to binding reduced by at least 25%.
- the invention also relates to the use of transcripts thereof and the proteins synthesizable therefrom and antisense constructs thereof for regulating, in particular increasing, the riboflavin synthesis in host cells in the sense of the teaching described herein.
- Processes for the introduction of mutations and subsequent measurement of the binding activity such as for example the implementation of a “gel-shift” experiment or of a “footprint” experiment (see e.g. Maniatis et al., 1989: “Molecular cloning, a laboratory manual”, 2 nd Edition, Cold Spring Harbours Laboratory, N.Y.), are known to those skilled in the art.
- the invention also relates to molecules binding to the aforesaid molecules and structures.
- Such molecules are suitable according to the invention for modifying, in particular suppressing, the function or activity of CcpC, or the homologs or orthologs.
- Preferably such molecules bind to at least one of the structures or molecules definable by the nucleotide sequences, selected from SEQ ID No.:1, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, and SEQ ID No.:15, in particular operator structures.
- the binding molecules are specific antibodies against the structures thus definable.
- a subject matter of the invention is a, monoclonal or polyclonal, antibody, which can bind specifically to one according to the aforesaid polyamino acid sequences or molecules.
- binding of the antibody to CcpC binding of the transcription factor to the operator sequences in the genes to be regulated, such as for example citB or citZ, is prevented.
- the modified nucleic acid molecules and modified host cells described above are used for increasing riboflavin synthesis.
- the present invention thus also relates to a process for the biotechnological synthesis of riboflavin, which in particular includes the following steps:
- a particular aspect of the invention is the fermentative production of riboflavin by means of the aforesaid modified host cells.
- riboflavin includes both riboflavin, and also flavin mononucleotide (FMN) and flavin adenine dinucleotide (FAD) and precursor molecules thereof (“precursors”), derivatives and/or salts of riboflavin, FMN or FAD.
- precursors precursor molecules thereof
- salts are in particular riboflavin-5-phosphate and sodium riboflavin-5-phosphate.
- Precursor molecules and derivatives of riboflavin, FMN or FAD include for example DRAPP, 5-amino-6-ribosylamino-2,4(1H,3H)-pyrimidinedione-5′-phosphate, 2,5-diamino-6-ribitylamino-4 (3H)-pyrimidinone-5′-phosphate, 5-amino-6-ribitylamino-2,4(1H,3H)-pyrimidinedione-5′-phosphate, 5-amino-6-ribitylamino-2,4(1H,3H)-pyrimidinedione, 6,7-dimethyl-8-ribityllumazine (DMRL) and flavoproteins.
- DRAPP 5-amino-6-ribosylamino-2,4(1H,3H)-pyrimidinedione-5′-phosphate
- 2,5-diamino-6-ribitylamino-4 (3H)-pyrimidinone-5′-phosphate 3,5-di
- Suitable carbon sources can be selected from compounds with 3, 5 or 6 carbon atoms, for example. D-glucose, glycerin, “thick juice”, dextrose, starch, saccharose or ribose. Preferably the carbon source is D-glucose.
- D-glucose glycerin
- glycerin glycerin
- thick juice dextrose
- starch starch
- saccharose or ribose ribose
- the carbon source is D-glucose.
- production substrate in connection with the process described herein are used mutually interchangeably.
- the (culture) medium for the process according to the invention for riboflavin synthesis by means of modified host cells all media suitable for riboflavin synthesis can be used.
- This is typically an aqueous medium which contains for example salts and substrate(s) and has a specific pH.
- the medium in which the substrate is converted into riboflavin is also referred to as the production medium.
- “Fermentation” or “production” or “fermentation process” in connection with the present invention refers to both the use of growing cells in a medium under conditions which are known to those skilled in the art, and also the use of no longer growing cells (so-called “resting cells”), after these have grown in the appropriate medium under the conditions known to those skilled in the art. These growing or no longer growing cells are used for the conversion of a suitable substrate into riboflavin, under conditions which are known to those skilled in the art.
- the synthesized riboflavin can be obtained/isolated from the host cells by suitable methods. This can for example mean the separation of the riboflavin from the production medium. Optionally, the riboflavin obtained can then be further processed, for example purified.
- the growth phase of the microorganisms normally takes place under aerobic conditions in an aqueous medium with addition of appropriate nutrients.
- the culturing can for example take place in a batch, fed-batch, semi-continuous or continuous process, fed-batch or semi-continuous being preferred.
- the duration of the culturing is for example ca. 10 hours to ca. 10 days, preferably ca. 4 to ca. 7 days, particularly preferably ca. 2 to ca. 6 days.
- the optimal conditions for the selected host cell Those skilled in the art know the optimal conditions for the selected host cell.
- the culturing is for example performed at a pH of ca. 7.0, preferably between ea. 6 to ca. 8, particularly preferably between ca. 6.5 to 7.5 and a suitable temperature from ca. 13° C. to ca. 70° C., preferably from ca. 35° C. to ca. 39° C., particularly preferably from ca. 30° C. to ca. 39° C., in particular from ca. 36° C. to ca. 39° C.
- the culture medium normally comprises D-glucose, glycerin, “thick juice”, dextrose, starch, saccharose or ribose as the carbon source, nitrogen sources, such as for example peptone, yeast extract or amino acids.
- salts can be present, for example magnesium sulfate, manganese sulfate, calcium phosphate or calcium carbonate.
- VF medium An example of fermentative production of riboflavin by means of cells of Bacillus subtilis is described in WO 04/113510 (VF medium), which is incorporated herein as a reference. This method should preferably be used for the present invention.
- the (modified) host cell is capable of increased riboflavin synthesis.
- the riboflavin yield of a host cell according to the invention in particular of the strain Bacillus subtilis , can be increased by at least 10%, compared with the yield of riboflavin of a non-modified or wild type cell. Increases by at least 20%, in particular at least 30%, 40%, 50%, 60%, 80% and more, are preferred.
- Analytical methods for the determination of the yield/productivity of riboflavin are known. Examples are HPLC or the use of indicator strains (see for example Bretzel et al., J. Ind. Microbiol. Biotechnol. 22, 19-26, 1999). After fermentation has taken place, the riboflavin produced is separated from the other components (culture medium, biomass, etc.), purified and the concentration determined by the known methods, a control reaction being performed with a wild type strain.
- 100 ⁇ trace element solution A 12.5 g MgCl 2 .6H 2 O; 0.55 g CaCl 2 ; 1.35 g FeCl 2 .6H 2 O; 0.1 g MnCl 2 .4H 2 O; 0.17 g/l ZnCl 2 ; 0.043 g CuCl 2 .2H 2 O; 0.06 g CoCl 2 .6H 2 O; 0.06 g Na 2 MoO 4 .2H 2 O; made up to 1 l H 2 O, autoclaved.
- 5 ⁇ minimal salt solution 0.057 M K 2 SO 4 ; 0.31 M K 2 HPO 4 .5H 2 O; 0.22 M KH 2 PO4; 0.017 M Na citrate.7H 2 O; 0.004 M MgSO 4 H 2 O, pH 7.0, autoclaved.
- 100 ⁇ trace element solution B 0.55 g CaCl 2 ; 0.17 g ZnCl 2 ; 0.043 g CuCl 2 .2H 2 O; 0.06 CoCl 2 .6H 2 O; 0.06 g Na 2 MoO 4 .2H 2 O; made up to 1 l H 2 O, autoclaved.
- Riboflavin screening medium 200 ml 10 ⁇ Spizizen salts; 10 ml 100 ⁇ trace element solution A; 2 ml 50% glucose; 36 ml 25% raffinose; 10 ml 10% yeast extract; made up to 1 l H 2 O.
- Spizizen minimal medium 100 ml 10 ⁇ Spizizen salts; 10 ml 50% glucose; 1 ml 40% sodium glutamate; 10 ml trace element solution A; made up to 1 l H 2 O.
- Riboflavin production in shaker flasks was tested as follows: 5 ml VY medium were inoculated starting from a frozen glycerin stock and cultured for 6-8 hrs at 37 C with shaking (280 rpm). The 5 ml cultures were used directly for the inoculation of 25 ml RSM medium in 250 ml flasks. After incubation for 48 hrs at 39 C with shaking (220 rpm), 500 ⁇ l of culture liquid were treated with 35 ml 4 N NaOH and shaken vigorously for one minute. The samples were treated with 465 ml potassium phosphate buffer (pH 6.8) and centrifuged for 5 mins at 13200 rpm.
- riboflavin, 6,7-dimethyl-8-ribityllumazin (DMRL) and oxolumazine content was determined by HPLC.
- a second culture sample was centrifuged (5 min, 13200 rpm) and the supernatant was used for the determination of residual glucose and raffinose. The determination of the values enabled the calculation of the yield.
- a UV signal at 280 nm was used for the detection. Riboflavin was detected as an isolated peak after 15.2 mins. The calibration of the method was performed with riboflavin from Fluka and was linear from 10 mg/l to 1 g/l. For the determination of glucose and raffinose from the culture broth, an Agilent 1100 HPLC system, to which a quaternary pump, an autosampler, and refractive index detector were attached, was also used. The separation was achieved on a CAPCELL PAK NH2 UG80 column (4.6 mm ⁇ 250 mm, 5 ⁇ ) from Shiseido. The optimal column temperature was 35 C. The mobile phase was a mixture of acetonitrile and deionized water in a ratio of 65/35. The flow rate was set at 1 ml/min. The injection volume was 5 ⁇ l. The refractive index detector signal was used for the detection. The method could be used for concentrations from 0.5 g/l to 30 g/l.
- subtilis 168 1 ⁇ l of a 100 ⁇ M solution of primer p436 (SEQ ID No.:16), 1 ⁇ l of a 100 ⁇ M solution of primer p439 (SEQ ID No.:17), 1 ⁇ l of a 10 mM dNTP solution, 5 ⁇ l 10 ⁇ buffer, and 0.5 ⁇ l Pfu polymerase (Stratagene) in 50 ⁇ l.
- the PCR reaction consisted of 35 cycles: (i) denaturation at 94° C. for 30 sec; (ii) annealing at 52° C. for 30 see; (iii) amplification at 72° C. for 1 min. Before the actual PCR reaction, the template DNA was denatured for 3 mins at 95° C.
- the primer pair primer p437 (SEQ ID No.:18) and primer p438 (SEQ ID No.:19) was used.
- the DNA fragment which coded for neomycin resistance gene cassette was prepared under the same conditions with the primer pair p9 (SEQ ID No.:20) and p10 (SEQ ID No.:21).
- the three DNA fragments were now bound together via their homologous, overlapping regions. For this, 50 ng of each of the DNA fragments purified by an agarose gel electrophoresis were used. Compared to the PCR conditions stated above, the amplification time was increased to 2.5 mins. All other parameters remained unchanged.
- primers p45 and p51 were used as the primer pair.
- the resulting PCR product was purified by means of the QiaQuick PCR purification kit from Qiagen. Competent B. subtilis 168 cells were transformed with 2 ⁇ g of purified product. Selection for neomycin-resistant colonies was performed on TBAB medium which contained 2 mg/l neomycin. By means of a further PCR (primer pair p45 and p10 under the aforesaid conditions) the genotype of selected neomycin-resistant transformants was confirmed. One positive transformant was given the designation BS5878.
- strain BS3914 and BS3917 are descendants of the riboflavin-overproducing strain BS3534 (for the construction of BS3534 see WO 2007/051552).
- BS3534 is based on the strain B. subtilis RB50, which was described in the patent EP 405370 and was deposited under the number NRRL B-18502.
- the plasmid pRF69 integrated in the riboflavin locus was replaced by a neomycin resistance gene cassette.
- the PCR method described above was used.
- the PCR product consisted of a 526 bp long 3′ region upstream from the riboflavin operon promoter (primer pair p50; SEQ ID No.:22 and p51; SEQ ID No.:23) on the genomic DNA of B. subtilis 168 and a 502 bp long 5′ region in the ribD gene (primer pair p44; SEQ ID No.:24 and p45; SEQ ID No.:25) on the genomic DNA of B.
- subtilis 168 which were fused with the neomycin resistance gene cassette (primer p9 and p10 on the plasmid pUB110) by means of PCR. The exact reaction conditions are described further above.
- the purified PCR product was used for the transformation of competent B. subtilis 168 cells. The selection took place on TBAB plates which contained 100 mg/l riboflavin and 2 mg/l neomycin. The genotype of grown colonies was confirmed by means of PCR and sequencing. One confirmed, isolated transformant was designated as BS3813.
- a PBS-1 phage lysate of BS3813 was prepared for the transfer of the construct into strain BS3534. The strain thus prepared was given the designation BS3798.
- the neomycin resistance cassette of the riboflavin-auxotrophic strain BS3813 was again replaced by a functional riboflavin operon.
- minimal medium plates (2 g/l glucose dissolved in the 1 ⁇ mineral salt solution—trace element solution) were used.
- the native promoter was replaced with the promoter of the veg gene of B. subtilis .
- a cytosine in the leader region was replaced with a thymidine (SEQ ID No.:26). Competent cells of the strain BS3813 were transformed with a DNA fragment which possessed the sequence according to SEQ ID No.:26.
- Transformed cells again possessed the ability to grow in a medium without addition of riboflavin.
- the genotype of grown colonies was confirmed by PCR and subsequent sequencing.
- One confirmed colony was designated as BS3953.
- a PBS-1 phage lysate of the strain BS3953 was used for the transduction of BS3798. The selection was performed as described above. Two types of transductants were isolated. In the first case, the inactivated spo0A gene of BS3798 had not been replaced with the wild type allele. One confirmed transductant received the designation BS3914. In the second case, the inactivated spo0A gene had been replaced with the active wild type form owing to the transfer of a larger piece of DNA during the transduction. One tested, Spo0A-positive mutant was named BS3917.
- BS3914 and BS3917 were now transducted with the lysate from BS5878. Once again, the selection took place on TBAB plates which contained 2 mg/l neomycin. The genotype of selected transductants was confirmed with the aforesaid PCR. Five confirmed transductants from the transduction of the strain BS3914 were given the designations BS5891, BS5893, BS5894 and BS5895. Four transductants which were derived from BS3917 received the designation BS5887 to BS5890.
- Transductants which are derived from the strain (BS3914) produced riboflavin with the same yield as the host strain BS3914.
- the ccpC knockout strains of the Spo0A-plus strain BS3917 produced riboflavin with a yield markedly improved over the host strain BS3917.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Wood Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE102008063234 | 2008-12-15 | ||
DE102008063234.1 | 2008-12-15 | ||
DE102008063234A DE102008063234B4 (de) | 2008-12-15 | 2008-12-15 | Biotechnologische Herstellung von Riboflavin mit hoher Ausbeute |
PCT/EP2009/008987 WO2010075960A2 (de) | 2008-12-15 | 2009-12-15 | Verfahren zur herstellung von riboflavin |
Publications (2)
Publication Number | Publication Date |
---|---|
US20110312026A1 US20110312026A1 (en) | 2011-12-22 |
US8759024B2 true US8759024B2 (en) | 2014-06-24 |
Family
ID=42025765
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/139,896 Active 2030-09-10 US8759024B2 (en) | 2008-12-15 | 2009-12-15 | Process for the production of riboflavin |
Country Status (7)
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102629304B (zh) * | 2012-04-05 | 2015-02-04 | 天津大学 | 基于基因组尺度代谢网络模型的代谢工程设计预测方法 |
CN102816823B (zh) * | 2012-09-18 | 2014-10-22 | 江南大学 | 利用多阶段转速调控策略提高Bacillus subtilis发酵生产核黄素产量的方法 |
CN107922464B (zh) * | 2015-08-28 | 2022-03-15 | 帝斯曼知识产权资产管理有限公司 | 经改进的维生素生产 |
CN108588108B (zh) * | 2018-05-04 | 2021-06-01 | 湖北大学 | 一种高效代谢甘油的芽胞杆菌的制备方法和应用 |
EA202191360A1 (ru) * | 2018-11-15 | 2021-08-11 | ДСМ АйПи АССЕТС Б.В. | Усовершенствованное получение рибофлавина |
KR102706898B1 (ko) * | 2022-06-07 | 2024-09-19 | 씨제이제일제당 주식회사 | 리보플라빈 생산능이 향상된 코리네박테리움 속 미생물 및 이를 이용한 리보플라빈을 생산하는 방법 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0821063A2 (en) | 1996-07-24 | 1998-01-28 | F. Hoffmann-La Roche Ag | Improved riboflavin production |
WO2003072785A2 (en) | 2002-02-27 | 2003-09-04 | Dsm Ip Assets B.V. | Fermentation process |
WO2006066925A2 (en) | 2004-12-22 | 2006-06-29 | Dsm Ip Assets B.V. | Novel genes involved in gluconeogenesis |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1066486C (zh) | 1989-06-22 | 2001-05-30 | 霍夫曼-拉罗奇有限公司 | 高产核黄素的细菌菌株 |
CN1809631B (zh) | 2003-06-18 | 2010-05-26 | 帝斯曼知识产权资产管理有限公司 | 用不能形成芽孢的微生物来生产泛酸盐/酯的方法 |
WO2007051552A1 (en) | 2005-11-02 | 2007-05-10 | Dsm Ip Assets B.V. | Modified transketolase and use thereof |
-
2008
- 2008-12-15 DE DE102008063234A patent/DE102008063234B4/de not_active Expired - Fee Related
-
2009
- 2009-12-15 KR KR1020117016203A patent/KR101739147B1/ko active Active
- 2009-12-15 WO PCT/EP2009/008987 patent/WO2010075960A2/de active Application Filing
- 2009-12-15 US US13/139,896 patent/US8759024B2/en active Active
- 2009-12-15 CN CN200980150515.7A patent/CN102245781B/zh active Active
- 2009-12-15 JP JP2011539963A patent/JP5813512B2/ja not_active Expired - Fee Related
- 2009-12-15 EP EP09796959A patent/EP2358893A2/de not_active Withdrawn
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0821063A2 (en) | 1996-07-24 | 1998-01-28 | F. Hoffmann-La Roche Ag | Improved riboflavin production |
WO2003072785A2 (en) | 2002-02-27 | 2003-09-04 | Dsm Ip Assets B.V. | Fermentation process |
WO2006066925A2 (en) | 2004-12-22 | 2006-06-29 | Dsm Ip Assets B.V. | Novel genes involved in gluconeogenesis |
Non-Patent Citations (11)
Title |
---|
Chen, X.H. et al., Database UniProt, "SubName: Full=CcpC", Database Accession No. A7Z428, (Oct. 23, 2007), 1 page. |
Chica et al. Curr Opin Biotechnol. Aug. 2005;16(4):378-84. * |
Foreign-language Written Opinion of the International Searching Authority for PCT/EP2009/008987, filed Jul. 5, 2010. |
Hyun-Jin, K. et al., "Regulation of the Bacillus subtilis ccpC Gene by ccpA and ccpC", Molecular Microbiology, vol. 43, No. 2, (Jan. 2002), pp. 399-410. |
International Search Report for PCT/EP20091008987, filed Jul. 5, 2010. |
Jourlin-Castelli, C. et al., "CcpC, a Novel Regulator of the LysR Family Required for Glucose Repression of the citB Gene in Bacillus subtilis", Journal of Molecular Biology, vol. 295, No. 4, (Jan. 28, 2000), pp. 865-878. |
Scanlan E. et al., Database UniProt, "RecName: Full-Uncharacterized HTH-type Transcriptional Regulator ykuM", Database Accession No. 034827, (May 30, 2000), 2 pages. |
Sen et al. Appl Biochem Biotechnol. Dec. 2007;143(3):212-23. * |
Vitreschak et al, "Regulation of riboflavin biosynthesis and transport genes in bacteria by transcriptional and translational attenuation", Nucleic Acids Research, 2002, vol. 30, No. 14, pp. 3141-3151. |
Yingbo, Z. et al., "Over-Expression of Glucose Dehydrogenase Imrpoved Cell Growith and Riboflavin Production in Bacillus subtilis", Biotechnology Letters, vol. 28, No. 20, (Aug. 16, 2006), pp. 1667-1672. |
Zhang, F. et al., "Knockout of the HprK Gene in Bacillus subtilis CcpA Mutant and Its Influence on Riboflavin Fermentation", Chinese Journal of Biotechnology, vol. 22, No. 4, (Jul. 1, 2006), pp. 534-538. |
Also Published As
Publication number | Publication date |
---|---|
DE102008063234B4 (de) | 2011-06-22 |
KR20110104955A (ko) | 2011-09-23 |
KR101739147B1 (ko) | 2017-05-23 |
EP2358893A2 (de) | 2011-08-24 |
WO2010075960A2 (de) | 2010-07-08 |
JP2012511898A (ja) | 2012-05-31 |
CN102245781A (zh) | 2011-11-16 |
WO2010075960A8 (de) | 2011-06-23 |
DE102008063234A1 (de) | 2010-06-17 |
WO2010075960A3 (de) | 2010-09-10 |
CN102245781B (zh) | 2015-11-25 |
JP5813512B2 (ja) | 2015-11-17 |
US20110312026A1 (en) | 2011-12-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10633684B2 (en) | Production of riboflavin | |
KR101558622B1 (ko) | mRNA의 안정화를 통한 표적 생성물의 증가된 제조 | |
US8759024B2 (en) | Process for the production of riboflavin | |
JP7497348B2 (ja) | リボフラビンの改善された産生 | |
CN107922464B (zh) | 经改进的维生素生产 | |
KR102434925B1 (ko) | 3-메틸-2-옥소뷰타노에이트 하이드록시 메틸트랜스퍼라아제의 활성이 강화된 미생물, 및 이의 용도 | |
KR102712136B1 (ko) | 바이오틴 신타제 활성을 갖는 폴리펩티드 변이체 및 이를 이용한 바이오틴 생산 방법 | |
KR101334169B1 (ko) | 글루코스신생합성에 관련된 신규 유전자 | |
EP2000477A1 (en) | Increased production of a target product via stabilization of mRNA | |
CN120290510A (zh) | 一种烟酰胺磷酸核糖转移酶的突变体及其应用 | |
EA013412B1 (ru) | Новый ген sms 27 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: DSM IP ASSETS B.V., NETHERLANDS Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:KIRCHNER, FLORIAN;MAUCH, KLAUS;SCHMID, JOACHIM;SIGNING DATES FROM 20110720 TO 20110725;REEL/FRAME:026835/0965 |
|
STCF | Information on status: patent grant |
Free format text: PATENTED CASE |
|
MAFP | Maintenance fee payment |
Free format text: PAYMENT OF MAINTENANCE FEE, 4TH YEAR, LARGE ENTITY (ORIGINAL EVENT CODE: M1551) Year of fee payment: 4 |
|
MAFP | Maintenance fee payment |
Free format text: PAYMENT OF MAINTENANCE FEE, 8TH YEAR, LARGE ENTITY (ORIGINAL EVENT CODE: M1552); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY Year of fee payment: 8 |